[HTML][HTML] A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage

JM Findlay, MR Middleton, I Tomlinson - Annals of Oncology, 2015 - Elsevier
Recent advances in next generation sequencing reinforce the potential for DNA sequence
markers to guide esophageal cancer management. We report the first systematic review and …

Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer

S Marsh, JA McKay, J Cassidy… - … journal of oncology, 2001 - spandidos-publications.com
Thymidylate synthase (TS) is an important target for chemotherapy drugs such as 5-
fluorouracil and raltitrexed. Over-expression of TS has been linked to chemotherapy …

Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review

DF Carr, G Whiteley, A Alfirevic… - The pharmacogenomics …, 2009 - nature.com
Genetic polymorphisms in the one-carbon folate pathway have been widely studied in
association with a number of conditions. Most of the research has focused on the 677C> T …

Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest

S Raz, D Sheban, N Gonen, M Stark, B Berman… - Cell death & …, 2014 - nature.com
Antifolates have a crucial role in the treatment of various cancers by inhibiting key enzymes
in purine and thymidylate biosynthesis. However, the frequent emergence of inherent and …

Novel opportunities for thymidylate metabolism as a therapeutic target

PM Wilson, W Fazzone, MJ LaBonte, J Deng… - Molecular cancer …, 2008 - AACR
For over 40 years, the fluoropyrimidine 5-fluorouracil (5-FU) has remained the central agent
in therapeutic regimens employed in the treatment of colorectal cancer and is frequently …

Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles

HR Luo, XM Lü, YG Yao, N Horie, K Takeishi… - Biochemical …, 2002 - Springer
The tandemly repeated 28-bp sequence in the 5′-terminal regulatory region of human
thymidylate synthase (TSER), which has been reported to be polymorphic in different …

Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients

A Gnoni, A Russo, N Silvestris, E Maiello… - Current Drug …, 2011 - ingentaconnect.com
Fluoropyrimidines and oxaliplatin continued to be the mainstay of therapeutic regimens in
the treatment of colorectal cancer (CRC). For this reason, pharmacokinetic and metabolism …

[HTML][HTML] Predictive and prognostic markers in colorectal cancer

PM Wilson, RD Ladner, HJ Lenz - Gastrointestinal cancer research …, 2007 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in both men and
women in the United States, with an estimated 153,760 new cases predicted for 2007. Since …

Impact of pharmacogenomics on clinical practice in oncology

S Marsh - Molecular Diagnosis & Therapy, 2007 - Springer
Multiple drug strategies for many cancer types are now readily available and there is a clear
need for tools to inform decision making on therapy selection. Although there is still a long …

Beyond thymidylate synthase and dihydrofolate reductase: impact of non-coding microRNAs in anticancer chemoresistance

J Ju - Current enzyme inhibition, 2012 - ingentaconnect.com
Chemoresistance is one of the major reasons for the failure of anticancer chemotherapy in
treating advanced stage cancer. The mechanism of chemoresistance to fluoropyrimidines …